Can HBsAg Be Used as a Viral Replication Marker in Chronic Hepatitis B Patients?
Journal Title: Viral Hepatitis Journal - Year 2017, Vol 23, Issue 2
Abstract
Objective: Monitoring hepatitis B virus (HBV) treatment responses and virus replication is performed with molecular tests. However, these tests are either expensive or invasive. A new and more practical marker is needed. We aimed to evaluate the correlation between serum hepatitis B surface antigen (HBsAg) and alanine aminotransferase (ALT) levels and HBV DNA level in hepatitis B e antigen (HBeAg) +/- patients and detect whether HBsAg can be used as a surrogate replication marker instead of HBV DNA. Material and Methods: A retrospective study was conducted in 59 chronic hepatitis B patients. Serum ALT, HBsAg and HBeAg levels and HBV DNA levels were recorded. The results were analysed with the Mann-Whitney U test and Spearman correlation coefficient. A p value of ≤0.05 was considered statistically significant. Sequential results were compared using Blant-Alpman plot. Results: The patients were grouped as HBeAg-positive (37.2%) and HBeAg-negative (62.8%). Serum ALT levels were elevated in 82% of HBeAg-positive and 70.2% of HBeAg-negative subjects. There was a statistically significant difference in HBsAg levels between the groups (p<0.05). However, there was no statistically significant difference in ALT and HBV DNA levels (p>0.05). A statistically significant negative correlation was detected between HBsAg and HBV DNA levels in HBeAg-positive patients. No correlation was found between HBsAg and HBV DNA levels in HBeAg-negative subjects (p<0.05). In both HBeAg-positive and -negative individuals, there was a positive correlation between serum ALT and HBV DNA levels (p<0.05). Blant-Alpman graph did not show an appropriate profile. Conclusion: We found a negative correlation between HBsAg and HBV DNA levels in HBeAg-positive patients. However, this correlation is not practical in monitoring treatment response and replication.
Authors and Affiliations
Emel UZUNOĞLU, Ahmet Melih ŞAHİN, Esin AVCI, Hakan KUTLU, Gökçe Gökçe GÜNTEPE
Direct-acting Antiviral Therapy for Mixed Genotype Chronic Hepatitis C Infection
Objectives: Literature data concerning the outcomes of direct acting antiviral (DAA) therapy in mixed genotype hepatitis C virus (HCV) infections are very limited, and the incidence of mixed HCV infection in Turkey is un...
A Misleading Parameter in the Diagnosis of Chronic Hepatitis B: Persistently Normal Transaminases
Objectives: Most of the patients with hepatitis B e (HBe)-negative hepatitis B have persistently normal transaminases (PNALT) levels. Patients, who have higher fibrosis and necroinflammatory activity scores, are at high...
Immunosuppressive Therapy and Hepatitis B Virus Reactivation
Reactivation of hepatitis B virus (HBV) refers to reappearance of active necroinflammatory disease of the liver in an individual at an inactive hepatitis B surface antigen carrier state or who is known to have resolved H...
Failure of Direct-Acting Antiviral Agents Due to Incomplete Hepatitis C Virus Genotyping
Current direct-acting antivirals (DAAs) have high success rates in the treatment of chronic hepatitis C virus (HCV) infection. However, 1-15% of patients fail to achieve viral eradication. Some factors may play a role in...
Circulating Glucose-Regulated Protein 78 Levels in Patients with Chronic Hepatitis B Infection
Objectives: The role of endoplasmic reticulum (ER) stress in the pathogenesis of hepatitis B virus (HBV) has been reported. However, serum levels of glucose-regulated protein (GRP) 78 which is an ER stress marker both in...